Routine data from hospital information systems can support patient recruitment for clinical studies

被引:51
作者
Dugas, Martin [1 ]
Lange, Matthias [2 ]
Mueller-Tidow, Carsten [3 ]
Kirchhof, Paulus [4 ]
Prokosch, Hans-Ulrich [5 ]
机构
[1] Univ Munster, Dept Med Informat & Biomath, D-48149 Munster, Germany
[2] Univ Klinikum Munster, IT Ctr, Munster, Germany
[3] Univ Klinikum Munster, Dept Med Hematol & Oncol A, Munster, Germany
[4] Univ Klinikum Munster, Dept Cardiol & Angiol, Munster, Germany
[5] Univ Erlangen Nurnberg, Chair Med Informat, Erlangen, Germany
关键词
HIGH-DOSE CYTARABINE; HIPAA PRIVACY RULE; PROLONGED MAINTENANCE; SINGLE-SOURCE; TRIALS; IMPACT; PARTICIPATION; MITOXANTRONE; INDUCTION; BARRIERS;
D O I
10.1177/1740774510363013
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background Delayed patient recruitment is a common problem in clinical studies. Hospital information systems (HIS) contain data items relevant for inclusion or exclusion criteria of these studies. Purpose We developed and assessed a system to support patient recruitment using HIS data. Methods We developed a workflow integrated in our HIS to notify study physicians about potential trial subjects. Automatic HIS database queries based on inclusion and exclusion criteria for each clinical study are performed regularly and generate e-mail notifications via a communication server. Study physicians can verify eligibility with a specific HIS study module. The system performance was assessed with a survey addressing utility, usability, stability, change in recruitment rate, and estimated time savings. Results During 10 months of operation, 1328 notifications were generated and 329 enrollments (25%) were documented for seven studies. Precision of alerts depends on availability of appropriate HIS items. Utility and usability were assessed as good, and stability as excellent. Users reported an increased patient recruitment rate for three studies. Three studies reported an estimated time saving of 10 min per recruited patient. The main perceived benefit was systematic identification of potentially eligible patients without time-consuming patient screening procedures in the different parts of the hospital. Limitations Notifications about potentially eligible patients depend on HIS data quality regarding inclusion/exclusion criteria, in particular, completeness, timeliness, and validity. Conclusions Routine HIS data can support patient recruitment for clinical studies by means of an automated notification workflow and efficient access to clinical data. Clinical Trials 2010; 7: 183-189. http://ctj.sagepub.com.
引用
收藏
页码:183 / 189
页数:7
相关论文
共 37 条
  • [1] Afrin Lawrence B, 2003, AMIA Annu Symp Proc, P16
  • [2] Ahmad Fawaz, 2005, AMIA Annu Symp Proc, P881
  • [3] [Anonymous], 2007, HEALTH TECHNOL ASSES
  • [4] [Anonymous], 1995, ONLINE J CURR CLIN T
  • [5] [Anonymous], 1996, Guideline for Good Clinical Practice
  • [6] Potential impact of the HIPAA privacy rule on data collection in a registry of patients with acute coronary syndrome
    Armstrong, D
    Kline-Rogers, E
    Jani, SM
    Goldman, EB
    Fang, JM
    Mukherjee, D
    Nallamothu, BK
    Eagle, KA
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2005, 165 (10) : 1125 - 1129
  • [7] Pilot study of a point-of-use decision support tool for cancer clinical trials eligibility
    Breitfeld, PP
    Weisburd, M
    Overhage, JM
    Sledge, G
    Tierney, WM
    [J]. JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION, 1999, 6 (06) : 466 - 477
  • [8] Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia
    Büchner, T
    Berdel, WE
    Schoch, C
    Haferlach, T
    Serve, HL
    Kienast, J
    Schnittger, S
    Kern, W
    Tchinda, J
    Reichle, A
    Lengfelder, E
    Staib, P
    Ludwig, WD
    Aul, C
    Eimermacher, H
    Balleisen, L
    Sauerland, MC
    Heinecke, A
    Wöermann, B
    Hiddemann, W
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (16) : 2480 - 2489
  • [9] 6-thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML):: A randomized trial of the German AML cooperative group
    Büchner, T
    Hiddemann, W
    Berdel, WE
    Wörmann, B
    Schoch, C
    Fonatsch, C
    Löffler, H
    Haferlach, T
    Ludwig, WD
    Maschmeyer, G
    Staib, P
    Aul, C
    Grüneisen, A
    Lengfelder, E
    Frickhofen, N
    Kern, W
    Serve, HL
    Mesters, RM
    Sauerland, MC
    Heinecke, A
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (24) : 4496 - 4504
  • [10] Butte AJ, 2000, J AM MED INFORM ASSN, P111